Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
The proposed demerger is the most significant corporate change for GSK in the last 20 years
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Subscribe To Our Newsletter & Stay Updated